These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 19584168

  • 1. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
    Elliott CS, Shinghal R, Presti JC.
    Clin Cancer Res; 2009 Jul 15; 15(14):4694-9. PubMed ID: 19584168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate cancer prevention and finasteride.
    D'Amico AV, Barry MJ.
    J Urol; 2006 Nov 15; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [Abstract] [Full Text] [Related]

  • 4. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH.
    J Natl Cancer Inst; 2007 Sep 19; 99(18):1366-74. PubMed ID: 17848668
    [Abstract] [Full Text] [Related]

  • 5. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA.
    J Urol; 2007 May 19; 177(5):1749-52. PubMed ID: 17437804
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.
    J Urol; 2008 Oct 19; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.
    J Urol; 2005 Sep 19; 174(3):877-81. PubMed ID: 16093979
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-grade prostate cancer and finasteride.
    Lebdai S, Bigot P, Azzouzi AR.
    BJU Int; 2010 Feb 19; 105(4):456-9. PubMed ID: 19930174
    [Abstract] [Full Text] [Related]

  • 11. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.
    Eur Urol; 2008 Apr 19; 53(4):750-7. PubMed ID: 17964070
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS, Swords K, Schultz H, Carson CC, Wallen EM.
    J Urol; 2009 Feb 19; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [Abstract] [Full Text] [Related]

  • 14. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.
    Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, Rittmaster R.
    J Urol; 2007 Jun 19; 177(6):2352-6. PubMed ID: 17509357
    [Abstract] [Full Text] [Related]

  • 15. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 19; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N, Fujimoto K, Yoshikawa M, Tanaka M, Hirao Y, Kondo H, Saito I.
    Hinyokika Kiyo; 2007 Jul 19; 53(7):459-65. PubMed ID: 17702178
    [Abstract] [Full Text] [Related]

  • 18. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    Nguyen CT, Yu C, Moussa A, Kattan MW, Jones JS.
    J Urol; 2010 Feb 19; 183(2):529-33. PubMed ID: 20006887
    [Abstract] [Full Text] [Related]

  • 19. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB, Parekh DJ.
    Curr Opin Urol; 2009 May 19; 19(3):238-42. PubMed ID: 19318950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.